GlassScriptPhysician profile
Michelle A Horvath
NPI 1689628638
$324.15
in general payments reported to CMS, 2019-2025
10 companies · $23.33 in 2025
The $23.33 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.69 · 2020: $39.45 · 2021: $28.46 · 2022: $85.45 · 2023: $21.04 · 2024: $27.73 · 2025: $23.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $80.15 | 2019-2023 | |
| Avion Pharmaceuticals | $67.91 | 2020-2021 | |
| Pfizer INC. | $63.41 | 2019-2025 | |
| Organon LLC | $33.87 | 2022-2024 | |
| Roche Diagnostics Corporation | $19.31 | 2019 | |
| Exeltis, USA INC. | $18.69 | 2022 | |
| Coopersurgical, INC. | $14.91 | 2024 | Endosee |
| Mission Pharmacal Company | $14.01 | 2019 | |
| Daiichi Sankyo INC. | $11.89 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Horvath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.